Ironwood (IRWD) Better-Than-Expects Q4 Results; On Track for FDA Submission of NDA for Linaclotide

March 3, 2011 8:16 AM

Ironwood Pharmaceuticals (NASDAQ: IRWD) reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found